view high-bandwidth site


Liquid micropiston technology for next-generation molecular assays and liquid biopsy


Wave 80 Biosciences develops next-generation molecular diagnostics products and technologies in infectious disease, autoimmune disease, and other human health conditions.

Through its EOSCAPE-HIV program, Wave 80’s talented scientists and engineers made major contributions toward reducing HIV transmission rates and improving patient outcomes in HIV. The EOSCAPE-HIV program has now led to exciting new research and product development initiatives in areas ranging from liquid biopsy to gastrointestinal infection to type 1 diabetes and other autoimmune diseases. The cornerstone of Wave 80's portfolio in these diverse disease categories is the company's groundbreaking Liquid Micropiston family of technologies.

EOSCAPE and curbing the HIV epidemic


While a growing number of HIV patients in the U.S. and around the world are receiving the antiretroviral drugs they need to live long, healthy lives, new HIV infections continue to occur, with an estimated 1.8 million new HIV infections in 2017 alone. Continued technological advances like the EOSCAPE-HIV are essential in reducing new HIV infections.

See the EOSCAPE-HIV video